(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 February 2009 (19.02.2009)

PCT

(10) International Publication Number
WO 2009/023623 A1

(51) International Patent Classification:
C07D 487/04 (2006.01)

(21) International Application Number:
PCT/US2008/072760

(22) International Filing Date: 11 August 2008 (11.08.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/955,250 10 August 2007 (10.08.2007) US

(71) Applicant *(for all designated States except US)*: **NEUROGEN CORPORATION** [US/US]; 35 Northeast Industrial Road, Branford, Connecticut 06405 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BAKTHAVATCHALAM, Rajagopal** [US/US]; 67 Hickory Lane, Madison, Connecticut 06443 (US). **IHLE, David C.** [US/US]; 242 Greens Farm Road, Branford, Connecticut 06405 (US). **CAPITOSTI, Scott M.** [US/US]; 684 Laurel Grove Road, Middletown, Connecticut 06457 (US). **WUSTROW, David J.** [US/US]; 32 Genesee Lane, Madison, Connecticut 06443 (US). **YUAN, Jun** [US/US]; 40 Spruce Hill Drive, Guilford, Connecticut 06437 (US).

(74) Agent: **FIDEL, Seth A.**; Cantor Colburn LLP, 20 Church Street, 22nd Flr., Hartford, Connecticut 06103 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*


Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(54) Title: HETEROARYL AMIDE ANALOGUES



Ia

or



Ib

(57) Abstract: Compounds, pharmaceutical compositions, and methods of use are disclosed for heteroaryl amide analogues of formula Ia and/or Ib: . In certain embodiments, the heteroaryl amide analogues are agonists and/or ligands of dopamine receptors and may be useful, inter alia, for the treatment of a condition responsive to P2X7 receptor modulation, for example, pain, inflammation, a neurological or neurodegenerative disorder, a cardiovascular disorder, an ocular disorder or an immune system disorder.

WO 2009/023623 A1